Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[Blaustein, in press]
The Year in Neuroendocrinology. JD Blaustein.
[Chair: John Joseph, in press]
Chair: John Joseph Kopchick, OH Univ/Edison Biotech Inst.
[Mollard, in press]
Pituitary somatotrophic cell networks. PE Mollard.
[Experimental models, in press]
Experimental models of pituitary growth hormone deficiency and correction with Interfering RNAs. ICAF Robinson.
[Tulsidas Dattani, in press]
Genetic mapping of pituitary ontogeny. M Tulsidas Dattani.
[S69-1]
Chemotherapy of aggressive pituitary tumors: pathologic predictors. A McCormack.
[S69-3]
Pituitary Tumor Shrinkage Following Medical Therapy. Authors: P Freda.
[Brew Atkinson and Findling, in press]
Optimum strategy for managing cyclical Cushing's disease. A Brew Atkinson, JW Findling.
[Nieman and Newell-Price, in press]
Cushing's syndrome: medical, surgical & other options. LK Nieman, JDC Newell-Price.
[Cook, in press]
Short & long-term issues in postoperative pituitary assessment. DM Cook.
[Arlt, in press]
Management of steroid replacement in adrenal insufficiency. W Arlt.
[OR15-2]
Targeting phosphorescent nanoparticles to corticotroph pituitary tumors. D Huang, S Young, H Hui, A Heaney.
[OR39-5]
High Incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas. MA Tichomirowa, AF Daly, A Barlier, ML Jaffrain-Rea, S Zacharieva, A Elenkova, et al.
[OR39-3]
Screening for over-expressed microRNAs in human sporadic pituitary adenomas. H Butz, I Liko, S Czirjak, P Igaz, V Zivkovic, M Korbonits, et al.
[P1-230]
Evidence for the release of bone morphogenetic protein (BMP) inhibitor from ovine pituitary cells. C Sallon, J Fontaine, C Taragnat.
[P1-545]
Hypothyroidism presenting as a pituitary tumor. SR Mian, V Gossain, HT Chang.
[P1-612]
Bone mineral density in pediatric patients with Cushing disease before and after surgical cure. MB Lodish, H Hsiao, A Sermpis, N Sinaii, A Rothenbuhler, M Keil, et al.
[P1-613]
PCOS-like clinical presentation of Cushing's syndrome in the absence of classical stigmata. EM Pardes, P San Martin, AM Fuentes, JE Yampey.
[P1-615]
Long-term follow-up of bone mineral density after treatment for Cushing's syndrome: evidence for spontaneous recovery. AW van der Eerden, JPJM van der Eerden, W Oyen, M Engels, AR Hermus, M den Heijer.
[P1-617]
The role of unilateral adrenalectomy associated with pituitary radiotherapy in the treatment of Cushing's disease patients. MC Machado, DJPC Romanholi, MAA Pereira, VAS Cescato, MCBV Fragoso, S Benabou, et al.
[P1-628]
Prolactin measurement during inferior petrosal sinus sampling improves the lateralization of pituitary adenomas in Cushing disease. GB Mulligan, C Faiman, M Gupta, B Hatipoglu, RJ Weil, AH Hamrahian.
[P1-629]
The role of inferior petrosal sinus sampling for ACTH-dependent Cushing's syndrome. N Perera, J Hetherington, EL Chua.
[P1-630]
Jugular venous sampling as an alternative to bilateral and simultaneous petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. RV Perez, MC Machado, DJPC Romanholi, VAS Cescato, P Puglia Jr, LR Salgado.
[P1-632]
Comparison of 1.5 and 3 Tesla MR imaging in detection of ACTH and GH secreting pituitary microadenomas. D Stobo, RS Lindsay, JM Connell, L Dunn, KP Forbes.
[P1-633]
The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease. R Farhat, A Alarifi, N Al Kahtani, I Kanaan, M-E Abouzeid, AS Alzahrani.
[P1-634]
The use of spoiled gradient recalled acquisition in magnetic resonance imaging for detection of adrenocorticotropin-secreting pituitary tumors: comparison to conventional spin echo technique. MC Machado, DJPC Romanholi, VAS Cescato, CC Leite, S Kodaira, LR Salgado.
[P1-635]
The value of 3 tesla magnetic resonance imaging and corticotropin releasing hormone stimulated 3 tesla magnetic resonance imaging for detection of microadenomas in Cushing's syndrome. D Erickson, BJ Erickson, R Watson, A Patton, J Atkinson, F Meyer, et al.
[P1-661]
The long-term medical therapy with octreotide is ineffective in reducing the tumor volume in patients with non-secreting pituitary adenomas not cured by surgery. A Fusco, S Piacentini, F Lugli, L Tilaro, A Giampietro, M Mormando, et al.
[P1-664]
Effect of pituitary surgery for non-functioning pituitary adenomas on pituitary function. MW O’Reilly, LA Behan, D Smith, CJ Thompson, A Agha.
[P1-672]
Visual function following surgery for clinically non-functioning pituitary tumours. S Deshpande, MA Karamat, AA Toogood, RD Mitchell, NJL Gittoes.
[P1-680]
A mother and daughter with somatotrophinomas familial or co-incidental? S Lim, MS Elston, JV Conaglen.
[P1-685]
Fibrotic transformation of invasive Nelson's adenoma as the result of treatment with octreotide and cabergoline. Z Abelev, A Gouller.
[P1-686]
Lightning conversion of a pituitary adenoma into carcinoma. MF Dolz, S Lesven, R Teissier, E Sonnet, N Roudaut, V Kerlan.
[P1-687]
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. C Hagen, S Hansen, C Hagen, M Andersen.
[P1-718]
Incidental GHRH-producing GHoma as screened by cavernous sinus sampling in a large series of pituitary tumors. H Katakami, S Yamada, S Hashida, A Matsuno.
[P1-673]
Clinical and hormonal outcome following surgery for non functioning pituitary adenomas (NFA): experience from a single Australian center. C Caputo, P McNeill, KW Ng, J Yang, W Inder.
[P2-113]
Everolimus blocks IGF-1 effects on cell viability of human non functioning pituitary adenomas in vitro independently of VEGF. MC Zatelli, M Minoia, C Filieri, F Tagliati, M Buratto, D Casini, et al.
[P2-114]
Anacardic acid induced secretory pituitary adenoma cell apoptosis by down regulation of surviving. S Sukumari Ramesh, N Singh, KM Dhandapani, J Vender.
[P2-116]
Epigenetic enzymes are upregulated in pituitary adenomas. D Tang, S Xu, R Fang, V Nose, R Carroll, Y Shi, et al.
[P1-718]
Incidental GHRH-producing GHoma as screened by cavernous sinus sampling in a large series of pituitary tumors. H Katakami, S Yamada, S Hashida, A Matsuno.
[P2-119]
Signaling pathway in pituitary tumorigenesis: evidence for interaction between iASPP and NFkappaB p65 subunit. EM Pinto, X Lu, NRC Musolino, IC Soares, A Wakamatsu, VAS Cescato, et al.
[P2-149]
SDF1 and CXCR4 expression in pituitary: role in the proliferation of human pituitary adenoma cells. F Barbieri, F Minuto, D Ferone, T Florio.
[P2-150]
Erk1/2 inhibition suppresses cell growth and enhances bromocriptine's inhibitory effect on pituitary tumor cells. S Chen, M Bangaru, J Woodliff, S Kansra.
[P2-151]
OTX and EMX genes in pituitary gland development and function. AH Mortensen, ML Brinkmeier, SW Davis, F Castinetti, MA Potok, SA Camper.
[P2-152]
Wnt-4 and Wnt-10a induction during estrogen-stimulated lactotroph proliferation. AA Giles, F Madec, S Friedrichsen, K Featherstone, T Chambers, J Resch, et al.
[P2-154]
The role of the forkhead transcription factor, during pituitary development. EM Patterson, DO Jung, BS Ellsworth.
[P2-156]
Expression of Foxd1 in the pituitary during embryonic development. SA Owusu, DO Jung, BS Ellsworth.
[P2-584]
GHRP-2 can stimulate TSH secretion from TSH secreting pituitary adenoma. S Sakihara, K Kageyama, S Takayasu, T Suda.
[P2-625]
Circadian levels of osteoprotegerin-RANKL tandem and bone markers before and after surgery in adult Cushing syndrome. B Estour, N Germain Zito, Y Khalfallah, B Galusca.
[P2-628]
Salivary cortisol in the outcome of Cushing's syndrome. EM Cardoso, AL Arregger, O Tumilasci, LN Contreras.
[P2-691]
Recurrence of Cushing's disease after a bilateral adrenalectomy. MM Szuszkiewicz, MJ McPhaul.
[P3-570]
Frequent phosphodiesterase 11A (PDE11A) gene mutations in patients with Carney Complex (CNC) due to PRKAR1A mutations and primary pigmented nodular adrenocortical disease (PPNAD): A digenic disorder? R Libe, A Horvath, A Fratticci, D Vezzosi, M Guillaud-Bataille, L Groussin, et al.
[P3-577]
A novel therapeutic agent for Cushing's disease: curcumin (Diferyloylmethone) inhibits proliferation and ACTH secretion in AtT20 cells. MLY Bangaru, J Woodliff, S Chen, H Raff, S Kansra.
[P3-628]
Posterior pituitary function in patients carrying structural hypothalamic-pituitary abnormalities. A Secco, F Napoli, N Di Iorgi, A Calcagno, E Calandra, C Frassinetti, et al.
[P3-662]
A unique case of Cushing's disease, cured by bilateral adrenalectomy and autotransplantation of adrenal gland. BR Shastri, SN Levine, NM Kaplan, I Muslow.
[P3-663]
False positive test for Cushing's syndrome: increased urinary cortisol due to topical steroid use. LA Fraser, SHM Van Uum.
[P3-664]
Silent corticotroph adenoma (SCA), bioinactive ACTH and acute extensive necrosis in an elderly male diabetic patient. S Gupta, JS Kerr, P Jayaramaiah, R Khardori.
[P3-665]
Adrenal incidentaloma masquerading as a glucocorticoid producing tumor in a patient with urosepsis and Cushing's disease. DD Clarke, PW Clyde, KMM Shakir.
[P3-666]
Severe osteoporosis with vertebral fractures as presenting symptoms of Cushing's disease. KN Jacob, B Cohan.
[P3-667]
Monitoring for Nelson's syndrome. ECI Hatfield, A Ghaffar, NM Martin, A Mehta, N Mendoza, F Roncaroli, et al.
[P3-673]
A phase II exploratory study of BIM23A760 in acromegalic patients: preliminary results of safety and efficacy after a single-dose administration. C Lesage, C Seymour, V Urbanavicius, A Beckers, G Kazanavicius, A Colao.
[P1-675]
Treatment outcomes of pituitary tumors at the University of Santo Tomas Hospital: 2004-2008. JS Fonte, EC Cunanan, BJ Matawaran, LB Mercado-Asis.
[P3-708]
Pituitary adenoma in children and adolescents. P Katavetin, P Cheunsuchon, M Misra, B Swearingen, ET Hedley-Whyte, LL Levitsky.
[P3-715]
Macroprolactinoma associated with aggressive Cushing's disease in a 12 year old child. CJ Peters, A Spada, M Korbonits, A White, MP Powell, MT Dattani.
Copyright © 2010. Sociedad Española de Endocrinología y Nutrición
